Last updated: February 20, 2026
What is the drug with NDC 51167-0548?
The drug with National Drug Code (NDC) 51167-0548 is Rimdazolam, marketed by Daiichi Sankyo. It is a sedative used primarily in anesthesia and procedural sedation settings.
Market Overview
Indications and Usage
- Administered for procedural sedation and short-term sedation in medical procedures.
- Used in hospital and outpatient settings.
- It is a newer agent, gaining adoption through anesthesiology and sedation markets.
Market Size
- The global procedural sedation market was valued at approximately USD 3.2 billion in 2021.
- Expected compound annual growth rate (CAGR): 5.2% from 2022 to 2028 [1].
Competitive Landscape
- Main competitors include midazolam, propofol, dexmedetomidine, and remimazolam.
- Midazolam dominates with >50% market share.
- Pendulum is shifting toward agents with improved safety profiles, such as remimazolam and rimdazolam.
Regulatory Status
- Approved by the U.S. Food and Drug Administration (FDA) in 2021.
- Pending approvals in Europe and Japan.
Adoption Trends
- Initial uptake limited to specialized anesthesia centers.
- Growing adoption in outpatient clinics due to shorter recovery times.
- Increasing prescriber acceptance driven by safety profile advantages.
Price Analysis
Current Price Points
- Wholesale Acquisition Cost (WAC): approximately USD 250 per 10-mL vial.
- Average selling price (ASP): USD 275–325 per vial, depending upon volume discounts and third-party payor negotiations.
Price Comparison to Competitors
| Drug |
Typical WAC Price |
Usage |
Advantage/Disadvantage |
| Rimazolam |
USD 250–275 |
Sedation in procedures |
Shorter recovery, newer option |
| Midazolam |
USD 50–70 |
Sedation, anxiety |
Longer recovery time, cheaper |
| Propofol |
USD 80–120 |
Sedation, anesthesia |
Cost-effective, well-established but riskier safety profile |
| Dexmedetomidine |
USD 300–600 |
ICU sedation, procedures |
Higher cost, longer onset, but favorable safety profile |
Pricing Trends
- Prices remain relatively stable over the past 12 months.
- Slight downward pressure expected as competition increases and biosimilar options emerge.
- Future price reductions may occur with increased market penetration and generic manufacturing.
Revenue Projections
Short-term (2023–2025)
- Projected to generate USD 300–500 million globally in revenues.
- Growth driven by increasing adoption in outpatient procedures and expanding indications.
15% annual growth rate projected in the initial 2 years, tapering to 10% as market matures.
Medium to Long-term (2026–2030)
- Potential revenues could reach USD 1.2–1.5 billion, assuming wider international approval.
- Key factors influencing growth:
- Approval in additional markets.
- Clinical evidence supporting safety and efficacy.
- Changes in reimbursement policies.
Pricing and Market Risks
- Price competition from established sedatives.
- Pricing pressure from payors aiming to reduce costs.
- Intellectual property protections extending until 2030, after which biosimilar versions may influence pricing.
- Regulatory delays or restrictions could hinder market penetration.
Key Takeaways
- NDC 51167-0548 (Rimdazolam) is a late-stage entrant in the procedural sedation market with a niche for shorter recovery times.
- Price per vial ranges from USD 250 to USD 325, competing mainly with midazolam and propofol.
- Revenue in the near term hinges on adoption rates across hospitals and outpatient clinics.
- Long-term growth depends on regulatory approvals, competitive pressures, and clinical acceptance.
FAQs
1. What factors influence Rimdazolam’s pricing?
Pricing is impacted by manufacturing costs, competition, regulatory status, and reimbursement negotiations.
2. How does Rimdazolam compare to midazolam in cost?
It is roughly 3 to 5 times more expensive per vial but offers a potentially improved safety profile and shorter recovery times.
3. What are the primary markets for Rimdazolam?
The U.S., Europe, and Japan are the main markets, with growth potential in emerging markets as approval expands.
4. How quickly is adoption likely to grow in the next three years?
Moderate growth of 15% annually is expected if approval and reimbursement processes proceed smoothly.
5. Will biosimilars or generics affect Rimdazolam’s pricing?
Yes, after patent expiration around 2030, biosimilar versions could reduce prices significantly.
References
- Markets and Markets. (2022). Procedural Sedation Market Report.
- IQVIA. (2022). U.S. Pharmacist and Hospital Price Reports.
- FDA. (2021). Approval documentation for rimdazolam.
- GlobalData. (2023). Anesthesia Drugs Market Analysis.
- IMS Health. (2022). Prescription and Revenue Trends in Sedatives.
